Chimin Health Management Past Earnings Performance
Past criteria checks 0/6
Chimin Health Management's earnings have been declining at an average annual rate of -20.1%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
-20.1%
Earnings growth rate
-19.8%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 4.2% |
Return on equity | -4.5% |
Net Margin | -9.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Chimin Health Management makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 905 | -84 | 315 | 31 |
31 Dec 23 | 895 | -65 | 294 | 29 |
30 Sep 23 | 875 | -2 | 276 | 26 |
30 Jun 23 | 844 | 9 | 265 | 25 |
31 Mar 23 | 774 | -2 | 249 | 27 |
31 Dec 22 | 837 | 34 | 260 | 28 |
30 Sep 22 | 952 | 84 | 264 | 32 |
30 Jun 22 | 1,001 | 107 | 275 | 31 |
31 Mar 22 | 1,130 | 178 | 277 | 31 |
31 Dec 21 | 1,098 | 148 | 273 | 30 |
30 Sep 21 | 1,059 | 117 | 258 | 27 |
30 Jun 21 | 1,069 | 108 | 241 | 27 |
31 Mar 21 | 1,000 | 54 | 219 | 23 |
31 Dec 20 | 878 | 6 | 214 | 22 |
30 Sep 20 | 798 | 63 | 206 | 23 |
30 Jun 20 | 735 | 48 | 210 | 22 |
31 Mar 20 | 710 | 51 | 225 | 23 |
31 Dec 19 | 771 | 69 | 231 | 21 |
30 Sep 19 | 737 | 36 | 222 | 20 |
30 Jun 19 | 728 | 28 | 219 | 18 |
31 Mar 19 | 726 | 32 | 211 | 18 |
31 Dec 18 | 698 | 32 | 200 | 17 |
30 Sep 18 | 692 | 50 | 194 | 17 |
30 Jun 18 | 668 | 61 | 163 | 28 |
31 Mar 18 | 634 | 55 | 163 | 23 |
31 Dec 17 | 603 | 53 | 160 | 19 |
30 Sep 17 | 572 | 55 | 155 | 15 |
30 Jun 17 | 527 | 48 | 169 | 0 |
31 Mar 17 | 481 | 43 | 158 | 0 |
31 Dec 16 | 450 | 41 | 154 | 0 |
30 Sep 16 | 432 | 38 | 153 | 0 |
30 Jun 16 | 433 | 42 | 149 | 0 |
31 Mar 16 | 438 | 48 | 152 | 0 |
31 Dec 15 | 449 | 52 | 154 | 0 |
30 Sep 15 | 462 | 53 | 148 | 0 |
30 Jun 15 | 467 | 51 | 153 | 0 |
31 Mar 15 | 486 | 58 | 151 | 0 |
31 Dec 14 | 488 | 58 | 154 | 0 |
31 Dec 13 | 559 | 81 | 167 | 0 |
Quality Earnings: 603222 is currently unprofitable.
Growing Profit Margin: 603222 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603222 is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare 603222's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603222 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 603222 has a negative Return on Equity (-4.45%), as it is currently unprofitable.